Filters
Once-weekly treatment with navepegritide was associated with significantly improved annualized growth velocity (AGV) in children with achondroplasia (ACH) compared with placebo, according to results from the pivotal ApproaCH trial presented at ENDO 2025.
In children living with HIV initiating antiretroviral therapy (ART), factors such as the ART regimen, age, BMI, and baseline CD4 count, among others, can predict treatment failure, according to a study.
The use of lenacapavir is highly efficacious in pregnant and lactating people (PLP), with zero participants acquiring HIV, as shown by the results of the PURPOSE 1 study.
New drug applications approved by US FDA as of 16-31 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
New drug applications approved by US FDA as of 1-15 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The preconception weight of parents, whether too low or too high, contributes to the risk of adverse birth outcomes, including perinatal death and birth defects, according to a study.
The use of oseltamivir for treating influenza episodes in children appears to lower the risk of serious neuropsychiatric events, according to a retrospective cohort study.
The E-STOP trial presented at ESHRE 2025 supports early antibiotic suspension in paediatric patients with cancer and febrile neutropenia (FN).
The incidence of febrile neutropenia (FN) is significantly lesser in children with solid tumours receiving pegylated filgrastim as primary prophylaxis following chemotherapy than in those assigned to filgrastim alone, reports a study. Moreover, no adverse events attributed to the study drug have been observed.
Treatment with emtricitabine/tenofovir alafenamide (F/TAF) and cobicistat-boosted atazanavir (ATV/c) or darunavir (DRV/c) maintained high rates of virologic suppression through 48 weeks in children living with HIV, based on two cohorts from the GS-US-216-0128 study presented at IAS 2025.
